AKR1A1 Antibody (3B08): sc-100500
- AKR1A1 Antibody (3B08) is a mouse monoclonal IgG1 κ, cited in 4 publications, provided at 100 µg/ml
- raised against recombinant AKR1A1 of human origin
- recommended for detection of AKR1A1 of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for AKR1A1 Antibody (3B08). This work is in progress.
AKR1A1 Antibody (3B08) is a mouse monoclonal IgG1 antibody that detects AKR1A1 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). AKR1A1, also known as aldo-keto reductase family 1 member A1, aldehyde reductase, dihydrodiol dehydrogenase 3, or alcohol dehydrogenase, is a crucial enzyme within the aldo-keto reductase family, which consists of soluble NADPH-dependent oxidoreductases that are vital for the metabolism of drugs, carcinogens, and reactive aldehydes. AKR1A1 primarily functions as a monomer, catalyzing the reduction of both xenobiotic and biogenic aldehydes and ketones to their corresponding alcohols, with a particular efficiency for medium-chain and aromatic aldehydes. AKR1A1 contributes to the biosynthetic pathways of cholesterol and triglycerides, while also participating in the activation of polycyclic aromatic hydrocarbons (PAHs), which are known to be environmental pollutants with potential carcinogenic effects. By facilitating the detoxification of harmful compounds, AKR1A1 plays an essential role in maintaining cellular homeostasis and protecting against oxidative stress, making AKR1A1 a critical target for research in pharmacology and toxicology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
AKR1A1 Antibody (3B08) References:
- The ubiquitous aldehyde reductase (AKR1A1) oxidizes proximate carcinogen trans-dihydrodiols to o-quinones: potential role in polycyclic aromatic hydrocarbon activation. | Palackal, NT., et al. 2001. Biochemistry. 40: 10901-10. PMID: 11535067
- The role of aldehyde reductase AKR1A1 in the metabolism of γ-hydroxybutyrate in 1321N1 human astrocytoma cells. | Alzeer, S. and Ellis, EM. 2011. Chem Biol Interact. 191: 303-7. PMID: 21276435
- [Effect of AKR1A1 knock-down on H2;O2; and 4-hydroxynonenal-induced cytotoxicity in human 1321N1 astrocytoma cells]. | Li, D., et al. 2013. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 29: 273-6. PMID: 23643085
- Metabolism of gamma hydroxybutyrate in human hepatoma HepG2 cells by the aldo-keto reductase AKR1A1. | Alzeer, S. and Ellis, EM. 2014. Biochem Pharmacol. 92: 499-505. PMID: 25256836
- A novel osteoporosis model with ascorbic acid deficiency in Akr1A1 gene knockout mice. | Lai, CW., et al. 2017. Oncotarget. 8: 7357-7369. PMID: 28060768
- Metabolic reprogramming by the S-nitroso-CoA reductase system protects against kidney injury. | Zhou, HL., et al. 2019. Nature. 565: 96-100. PMID: 30487609
- AKR1A1 Variant Associated With Schizophrenia Causes Exon Skipping, Leading to Loss of Enzymatic Activity. | Iino, K., et al. 2021. Front Genet. 12: 762999. PMID: 34938315
- Kefir peptides ameliorate osteoporosis in AKR1A1 knockout mice with vitamin C deficiency by promoting osteoblastogenesis and inhibiting osteoclastogenesis. | Chang, GR., et al. 2022. Biomed Pharmacother. 156: 113859. PMID: 36252352
- Aldo-keto reductase family 1 member A1 (AKR1A1) exerts a protective function in alcohol-associated liver disease by reducing 4-HNE accumulation and p53 activation. | Lan, YW., et al. 2024. Cell Biosci. 14: 18. PMID: 38308335
- AKR1A1 and Kidney Disease: Promise and Perils of the Multiverse. | Breyer, MD. 2024. Diabetes. 73: 1046-1047. PMID: 38900956
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AKR1A1 Antibody (3B08) | sc-100500 | 100 µg/ml | $333.00 |